Dr. med. Aurelius Omlin
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015; 26:1589-604.
03.06.2015Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
03.06.2015Ann Oncol 2015; 26:1589-604
Tombal B, Padhani A R, Olmos D, Oh W K, Nilsson S, Mastris K, Logothetis C J, Lecouvet F E, James N D, Hussain M, Parker C, Rubin M A, Tannock I F, Sweeney C J, Suzuki H, Sternberg C N, Small E J, Shore N D, Sella A, Scher H I, Schalken J A, Heidenreich A, Gleave M E, Smith M R, Sartor O, Nelson P S, Halabi S, Fizazi K, Efstathiou E, de Bono J S, Attard G, Omlin Aurelius, Soule H R, Akaza H, Fanti S, Eeles R A, Drake C G, De Santis M, Davis I D, Daugaard G, Chinnaiyan A M, Beltran H, Beer T M, Gillessen Sommer Silke
Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases
Desax M, Hundsberger T, Rothermundt C, Omlin A, Gillessen Sommer S. Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases. Clin Genitourin Cancer 2015; 13:e385-6.
01.05.2015Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases
01.05.2015Clin Genitourin Cancer 2015; 13:e385-6
Desax Marie-Claire, Hundsberger Thomas, Rothermundt Christian, Omlin Aurelius, Gillessen Sommer Silke
Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel
Omlin A, Sartor O, Rothermundt C, Cathomas R, de Bono J, Shen L, Su Z, Gillessen Sommer S. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Clin Genitourin Cancer 2015
30.01.2015Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel
30.01.2015Clin Genitourin Cancer 2015
Omlin Aurelius, Sartor Oliver, Rothermundt Christian, Cathomas Richard, de Bono Johann S, Shen Liji, Su Zhen, Gillessen Sommer Silke
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer
Pezaro C, Sohaib A, de Bono J, Dearnaley D, Parker C, Lorente D, Bianchini D, Attard G, Mukherji D, Perez-Lopez R, Omlin A, Tunariu N. Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. Clin Radiol 2014
30.12.2014Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer
30.12.2014Clin Radiol 2014
Pezaro C, Sohaib A, de Bono J S, Dearnaley D, Parker C, Lorente D, Bianchini D, Attard G, Mukherji D, Perez-Lopez R, Omlin Aurelius, Tunariu N
PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
Ferraldeschi R, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, Altavilla A, Mateo J, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, de Bono J. PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. Eur Urol 2014
04.11.2014PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
04.11.2014Eur Urol 2014
Ferraldeschi Roberta, Sideris Spyridon, Bianchini Diletta, Grist Emily, Thway Khin, Perez Lopez Raquel, Tunariu Nina, Parker Chris, Dearnaley David, Reid Alison, Attard Gerhardt, Altavilla Amelia, Mateo Joaquin, Nava Rodrigues Daniel, Riisnaes Ruth, Miranda Susana, Figueiredo Ines, Rescigno Pasquale, Ravi Praful, Pezaro Carmel, Omlin Aurelius, Lorente David, Zafeiriou Zafeiris, de Bono Johann
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
Lorente D, de Bono J, Gillessen Sommer S, Dearnaley D, Parker C, Tunariu N, Zafeirou Z, Altavilla A, Mateo J, Perez R, Pezaro C, Ferraldeschi R, Omlin A, Attard G. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 2014
14.10.2014Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
14.10.2014Br J Cancer 2014
Lorente D, de Bono J, Gillessen Sommer Silke, Dearnaley D, Parker C, Tunariu N, Zafeirou Z, Altavilla A, Mateo J, Perez R, Pezaro C, Ferraldeschi R, Omlin Aurelius, Attard G
Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading
Weisshaupt C, Hitz F, Albrich W, Omlin A. Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading. BMJ Case Rep 2014; 2014
22.09.2014Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading
22.09.2014BMJ Case Rep 2014; 2014
Weisshaupt Christian, Hitz Felicitas, Albrich Werner, Omlin Aurelius
Tumor clone dynamics in lethal prostate cancer
Carreira S, Demichelis F, S de Bono J, Tunariu N, Flohr P, Rodrigues D, Omlin A, Pezaro C, Frenel J, Lorente D, Prandi D, Miranda S, Ferraldeschi R, Grist E, Goodall J, Romanel A, Attard G. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014; 6:254ra125.
17.09.2014Tumor clone dynamics in lethal prostate cancer
17.09.2014Sci Transl Med 2014; 6:254ra125
Carreira Suzanne, Demichelis Francesca, S de Bono Johann, Tunariu Nina, Flohr Penelope, Rodrigues Daniel Nava, Omlin Aurelius, Pezaro Carmel, Frenel Jean-Sebastien, Lorente David, Prandi Davide, Miranda Susana, Ferraldeschi Roberta, Grist Emily, Goodall Jane, Romanel Alessandro, Attard Gerhardt
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
Blagden S, Spicer J, Twelves C, Jones K, Prince J, Inatani M, Shiokawa R, Noguchi K, Pope L, Riisnaes R, Swales K, Decordova S, Anthoney A, Pinato D, Zivi A, Stavraka C, Josephs D, Omlin A, Banerji U. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. Clin Cancer Res 2014; 20:5908-17.
17.09.2014First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
17.09.2014Clin Cancer Res 2014; 20:5908-17
Blagden Sarah, Spicer James, Twelves Chris, Jones Keith, Prince Jenny, Inatani Michiyasu, Shiokawa Rie, Noguchi Kohei, Pope Lorna, Riisnaes Ruth, Swales Karen, Decordova Shaun, Anthoney Alan, Pinato David J, Zivi Andrea, Stavraka Chara, Josephs Debra, Omlin Aurelius, Banerji Udai
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
Mukherji D, Omlin A, Pezaro C, Shamseddine A, de Bono J. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. Cancer Metastasis Rev 2014; 33:555-66.
01.09.2014Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
01.09.2014Cancer Metastasis Rev 2014; 33:555-66
Mukherji Deborah, Omlin Aurelius, Pezaro Carmel, Shamseddine Ali, de Bono Johann
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio
Templeton A, Tannock I, de Bono J, Attard G, Vera-Badillo F, Leibowitz-Amit R, McNamara M, Omlin A, Pezaro C, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 2014; 120:3346-52.
03.07.2014Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio
03.07.2014Cancer 2014; 120:3346-52
Templeton Arnoud, Tannock Ian F, de Bono Johann S, Attard Gerhardt, Vera-Badillo Francisco E, Leibowitz-Amit Raya, McNamara Mairead G, Omlin Aurelius, Pezaro Carmel, Amir Eitan
Circulating tumor cells: a multifunctional biomarker
Yap T, Lorente D, Omlin A, Olmos D, de Bono J. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 2014; 20:2553-68.
15.05.2014Circulating tumor cells: a multifunctional biomarker
15.05.2014Clin Cancer Res 2014; 20:2553-68
Yap Timothy A, Lorente David, Omlin Aurelius, Olmos David, de Bono Johann S
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study
Loriot Y, Ouatas T, Holtkamp G, Baron B, Heeringa M, Baskin-Bey E, James N, Omlin A, Molife R, Van den Brande J, Jones R, Fizazi K, de Bono J. Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs 2014; 32:995-1004.
27.04.2014Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study
27.04.2014Invest New Drugs 2014; 32:995-1004
Loriot Yohann, Ouatas Taoufik, Holtkamp Gertjan M, Baron Benoit, Heeringa Marten, Baskin-Bey Edwina, James Nicholas D, Omlin Aurelius, Molife Rhoda L, Van den Brande Jan, Jones Robert J, Fizazi Karim, de Bono Johann S
Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice
Blum D, Strasser F, Kaasa S, Hayoz S, Dewolf-Linder S, Mingrone W, von Moos R, Walker J, Omlin A, Koeberle D, Ribi K. Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice. Support Care Cancer 2014; 22:2425-34.
05.04.2014Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice
05.04.2014Support Care Cancer 2014; 22:2425-34
Blum D, Strasser Florian, Kaasa S, Hayoz S, Dewolf-Linder S, Mingrone W, von Moos R, Walker J, Omlin Aurelius, Koeberle D, Ribi K
Autonomic Dysfunction in Cancer Cachexia Coincides With Large Fiber Polyneuropathy
Hundsberger T, Omlin A, Hägele-Link S, Vehoff J, Strasser F. Autonomic Dysfunction in Cancer Cachexia Coincides With Large Fiber Polyneuropathy. J Pain Symptom Manage 2014; 48:611-618.
04.04.2014Autonomic Dysfunction in Cancer Cachexia Coincides With Large Fiber Polyneuropathy
04.04.2014J Pain Symptom Manage 2014; 48:611-618
Hundsberger Thomas, Omlin Aurelius, Hägele-Link Stefan, Vehoff Jochen, Strasser Florian
Maligne spinale Kompression
Omlin A, Forster T, Steinen M, Brügge D, Fretz C, Gillessen S, Hundsberger T. Maligne spinale Kompression - Prävention, Erkennung und "State of the Art"-Behandlung. Schweiz Med Forum 2014; 14:820-825.
05.02.2014Maligne spinale Kompression
05.02.2014Schweiz Med Forum 2014; 14:820-825
Omlin Aurelius, Forster Thomas, Steinen MN, Brügge D, Fretz Ch, Gillessen S, Hundsberger Th
Abiraterone--what is wrong with the adrenal glands?
Schmid S, Fornaro J, Rothermundt C, Omlin A, Brändle M, Rupp N, Gillessen Sommer S. Abiraterone--what is wrong with the adrenal glands?. Clin Genitourin Cancer 2014; 12:e133-7.
04.02.2014Abiraterone--what is wrong with the adrenal glands?
04.02.2014Clin Genitourin Cancer 2014; 12:e133-7
Schmid Sabine, Fornaro Jürgen, Rothermundt Christian, Omlin Aurelius, Brändle Michael, Rupp Niels J, Gillessen Sommer Silke
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
Molife L, Pelling K, Temple G, Heath C, Wheatley D, Oommen N, Thompson E, Jenkins P, Hickish T, Pedley I, O'Sullivan J, Olmos D, Fong P, Lumsden G, Bloomfield D, Karavasilis V, Jones R, Omlin A, de Bono J. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol 2014; 10:219-31.
01.02.2014Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
01.02.2014Future Oncol 2014; 10:219-31
Molife L Rhoda, Pelling Katy, Temple Graham, Heath Catherine, Wheatley Duncan, Oommen Nikhil, Thompson Emilda, Jenkins Peter, Hickish Tamas, Pedley Ian, O'Sullivan Joe M, Olmos David, Fong Peter C, Lumsden Graeme, Bloomfield David, Karavasilis Vasilios, Jones Rob J, Omlin Aurelius, de Bono Johann S
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014; 6:3-14.
01.02.2014Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
01.02.2014Ther Adv Urol 2014; 6:3-14
Omlin Aurelius, Pezaro Carmel, Gillessen Sommer Silke
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
Leibowitz-Amit R, de Bono J, Tannock I, Sridhar S, Knox J, Attard G, Seah J, Vera-Badillo F, Keizman D, Atenafu E, Pezaro C, Omlin A, Templeton A, Joshua A. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2014; 25:657-62.
23.01.2014Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
23.01.2014Ann Oncol 2014; 25:657-62
Leibowitz-Amit R, de Bono J S, Tannock I F, Sridhar S S, Knox J J, Attard G, Seah J-A, Vera-Badillo F, Keizman D, Atenafu E G, Pezaro C, Omlin Aurelius, Templeton Arnoud, Joshua A M